Phase II trial of sunitinib malate in patients with temozolomide refractory recurrent high-grade glioma

被引：0
|
作者：
Neyns, B. [1 ,2 ]
Chaskis, C. [1 ,2 ]
Dujardin, M. [1 ,2 ]
Everaert, H. [1 ,2 ]
Sadones, J. [1 ,2 ]
Nupponen, N. N. [1 ,2 ]
Michotte, A. [1 ,2 ]
机构：
[1] UZ Brussel, Brussels, Belgium
[2] Univ Helsinki, Helsinki, Finland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2038
引用
收藏
页数：2
相关论文
共 50 条
  • [31] A phase II study of anlotinib in the treatment of recurrent high-grade glioma
    Dai, H.
    Zhang, M.
    Zhang, Q.
    Zhao, S.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S521 - S522
  • [32] A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas
    Kreisl, Teri N.
    Kotliarova, Svetlana
    Butman, John A.
    Albert, Paul S.
    Kim, Lyndon
    Musib, Luna
    Thornton, Donald
    Fine, Howard A.
    [J]. NEURO-ONCOLOGY, 2010, 12 (02) : 181 - 189
  • [33] A PHASE I TRIAL OF TTFIELDS WITH AND WITHOUT CONCOMITANT TEMOZOLOMIDE AND BEVACIZUMAB IN PEDIATRIC PATIENTS WITH HIGH-GRADE GLIOMA
    Hanson, Derek
    [J]. NEURO-ONCOLOGY, 2018, 20 : 66 - 67
  • [34] Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas
    Fine, HA
    Wen, PY
    Maher, EA
    Viscosi, E
    Batchelor, T
    Lakhani, N
    Figg, WD
    Purow, BW
    Borkowf, CB
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) : 2299 - 2304
  • [35] Efficacy of Temozolomide Treatment in Patients with High-grade Glioma
    Oshiro, Shinya
    Tsugu, Hitoshi
    Komatsu, Fuminari
    Ohmura, Tadahiro
    Ohta, Mika
    Sakamoto, Seisaburou
    Fukushima, Takeo
    Inoue, Tooru
    [J]. ANTICANCER RESEARCH, 2009, 29 (03) : 911 - 917
  • [36] Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma
    Abacioglu, Ufuk
    Caglar, Hale B.
    Yumuk, Perran F.
    Akgun, Zuleyha
    Atasoy, Beste M.
    Sengoz, Meric
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2011, 103 (03) : 585 - 593
  • [37] Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma
    Ufuk Abacioglu
    Hale B. Caglar
    Perran F. Yumuk
    Zuleyha Akgun
    Beste M. Atasoy
    Meric Sengoz
    [J]. Journal of Neuro-Oncology, 2011, 103 : 585 - 593
  • [38] Temozolomide Rechallenge in Patients With Recurrent High-Grade Glioma Treated With Re-Irradiation
    Basree, M. M.
    Ali, A.
    Garg, S.
    Glass, J.
    Kim, L.
    Farrell, C.
    Evans, J.
    Judy, K.
    Andrews, D. W.
    Shi, W.
    Werner-Wasik, M.
    Palmer, J. D.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E587 - E588
  • [39] Phase II trial of temozolomide in patients with progressive low-grade glioma
    Quinn, JA
    Reardon, DA
    Friedman, AH
    Rich, JN
    Sampson, JH
    Provenzale, JM
    McLendon, RE
    Gururangan, S
    Bigner, DD
    Herndon, JE
    Avgeropoulos, N
    Finlay, J
    Tourt-Uhlig, S
    Affronti, ML
    Evans, B
    Stafford-Fox, V
    Zaknoen, S
    Friedman, HS
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (04) : 646 - 651
  • [40] Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma
    Verhoeff, J. J. C.
    Lavini, C.
    van Linde, M. E.
    Stalpers, L. J. A.
    Majoie, C. B. L. M.
    Reijneveld, J. C.
    van Furth, W. R.
    Richel, D. J.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 (08) : 1723 - 1727
12345